Arizona State University
  • ASU Home
  • ASU A-Z Index
  • My ASU
  • Colleges & Schools
  • Directory
  • Map
  • SIGN IN
 

For the media

  • News Releases
  • Image Downloads
  • Media Contacts
  • ASU Facts
  • Visiting Campus
  • Video Archive

ASU News

  • University
  • Arts / Culture
  • Business
  • Engineering
  • Law
  • Humanities
  • Health care
  • Research
    • Bioscience/Biotech
    • Life Science
    • Social Science
    • Earth/Space
    • Sustainability/ Environment
    • Engineering
    • Grants / Awards
  • Science
  • Administration
  • Faculty / Staff
  • Students
  • Alumni
  • Community
  • Sports
  • Photo Gallery
  • More Categories

About News

  • Site Contact
  • News Staff
  • ASU Insight
  • Other Publications

Subscriptions

  • E-mail and Feeds

ASUNews

February 09, 2009
Print content Print this    Syndicate content Newsfeeds
Home

ASU and TGEN team up to find a treatment for progressive cognitive impairment

A new collaborative study between Arizona State University and Translational Genomics Research Institute (TGen) has reported that a safe and effective drug used to treat vascular problems in the brain improved learning and memory in middle-aged rats. The finding supports the scientific quest for a substance that could treat progressive cognitive impairment, cushion the cognitive impact of normal aging, or even enhance learning and memory throughout the life span. "Fasudil shows great promise as a cognitive enhancer during aging,'' said Dr. Heather Bimonte-Nelson, an Assistant Professor in ASU's Department of Psychology. "The effects in our aging-animal model were robust, showing enhancements in both learning and two measures of memory. The possibility that these findings may translate to benefits to human brain health and function is very exciting." Hydroxyfasudil inhibits the activity of Rho-kinase enzymes, which have been shown to elevate Rac1, a vital protein that supports key cellular functions. "If Fasudil proves to be safe and effective in enhancing learning and memory, it could represent a viable new option for the prophylactic treatment of disorders with a cognitive decline component. This could include diseases like Alzheimer's as well as general age-related impairment. In short, it may be a new pharmaceutical weapon that could be used even before the occurrence of symptoms," said Dr. Matthew Huentelman, an Investigator in TGen's Neurogenomics Division.
Share this story:
  • Email this pageEmail this page
  • Delicious
  • Digg
  • Reddit
  • Magnoliacom
  • Newsvine
  • Furl
  • Facebook
  • Google
  • Yahoo
  • Technorati
  • Icerocket
  • Copyright & Trademark
  • Accessibility
  • Privacy
  • Emergency
  • Contact ASU

ASU News
Gary Campbell, Executive Editor/Publisher | (480) 965-7209 | Email
Centerpoint, suite 416 | Map
Campus mail: 5011 ­ASU Insight
Phone: (480) 965-3502
FAX: (480) 965-2159

sod110